Ciclesonide vs Mometasone Preference in Allergic Rhinitis

Phase 3, randomised, open-label trial of ciclesonide in perennial allergic rhinitis (PAR) (2 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Total Preference Composite Score Assessed at the End of the Study at Day 43 and Change From Baseline in Regimen Attributes Composite Score at Day 42. Started Jul 2011; status: completed.